During Friday’s Current trade, Shares of Xylem Inc (NYSE:XYL), gain 0.62% to $32.33.
Xylem Inc. (XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, recently declared that it has been named to the Dow Jones Sustainability Index (DJSI) for North America for the fourth successive year in recognition of its ongoing sustainability initiatives. The Company was also comprised of again in the FTSE4Good Index Series, which recognizes companies that have met stringent environmental, social and governance practices.
The Dow Jones Sustainability Index for North America tracks the performance of the top 20 percent of the 600 largest Canadian and United States companies in the S&P Global Broad Market Index that lead the field in terms of sustainability. The result of the Corporate Sustainability Assessment by RobecoSAM, an investment boutique focused exclusively on sustainability investing, provides an in-depth analysis of economic, environmental and social criteria, such as corporate governance, water-related risks and stakeholder relations, with a special focus on industry-specific risks and opportunities.
Xylem Inc. engages in the design, manufacture, and application of engineered technologies for the water and wastewater applications. The company operates in two segments, Water Infrastructure and Applied Water. The Water Infrastructure segment offers various products, counting water and wastewater pumps, treatment and testing equipment, and controls and systems, in addition to filtration, disinfection, and biological treatment equipment under the Flygt, WEDECO, Godwin, WTW, Sanitaire, YSI, and Leopold names for transportation, treatment, and testing of water and wastewater for public utilities and industrial applications.
Shares of Kimberly Clark Corp (NYSE:KMB), declined -0.18% to $103.47, during its current trading session.
Kimberly-Clark and its Digital Innovation Lab, or D’Lab, has renewed its global call for open-source innovation to the consumer package goods category through its K-Challenge. The K-Challenge, now in its third year, invites the best start-up companies and entrepreneurs from around the globe to assist identify potential “Tech for Life” solutions for the company and its well-known global brands such as Kleenex, Huggies, Depend and Kotex.
The K-Challenge is an open invitation to entrepreneurs and technology startups to bring innovation to the consumer goods category. The program is primarily focused on inviting startup companies with proven solutions in five key areas:
- Location-based Technologies.
- Omni-channel Commerce Experiences.
- Data & Predictive Analytics.
- Content & Media Experiences.
- Internet-of-Things/Wearables/Connected Devices.
Kimberly-Clark Corporation, together with its auxiliaries, manufactures and markets personal care, consumer tissue, and K-C professional products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Kotex, U by Kotex, Intimus, Depend, Plenitud, Poise, and other brands.
Equinix Inc (NASDAQ:EQIX), during its Thursday’s current trading session decreased -0.40% to $284.01.
Equinix, Inc. (EQIX), the global interconnection and data center company, declared that acting through its Japanese partner it has commenced a cash tender offer for all issued and outstanding shares of Tokyo-based Bit-isle Inc. (President and CEO: Kohei Terada, TSE: 3811). The offer price is JPY922 per share, in an all cash transaction totaling 33.3 billion Japanese Yen or about $280 million U.S. dollars. The tender offer period is predictable to run from September 9, 2015 to October 26, 2015, unless the tender offer period is extended. The offer is conditioned on, among other things, the tender by Bit-isle shareholders of more than 66 2/3% of the Bit-isle shares. If the conditions to the tender offer are satisfied, Equinix will move forward to acquire any remaining shares under Japanese corporate law and anticipates to complete the acquisition of Bit-isle by early 2016. The Board of Directors of Bit-isle has agreed to endorse the tender offer. Additionally, the major shareholders of Bit-isle, Warehouse Terrada, Mr. Kohei Terada and Mr. Yasunobu Terada, have agreed to tender all of their shares, representing 29.74% of Bit-isle shares on a fully diluted basis.
Equinix, Inc. is a publicly owned real estate investment trust. It provides data center services to protect and connect the information assets for the enterprises, financial services companies, and content and network providers primarily in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific.
Finally, Peregrine Pharmaceuticals (NASDAQ:PPHM), decreased -1.68%, to $1.17.
Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, recently declared financial results for the first quarter of fiscal year (FY) 2016 ended July 31, 2015, and offered an update on its advancing clinical pipeline and other corporate developments.
Highlights Since April 30, 2015:
“Over the years, Peregrine’s foundational science and positive clinical results have comprising pointed to bavituximab’s potential as a high-value, next-generation anti-cancer agent,” said Steven W. King, president and chief executive officer of Peregrine. “In the last three months, these achievements have compelled others to align with us as we continue to develop bavituximab. In May, Peregrine declared an exciting partnershipwith Memorial Sloan Kettering Cancer Center to evaluate combinations of bavituximab with other checkpoint inhibitors and immune stimulatory agents for the purpose of developing new and increasingly effective anti-cancer treatments. Only three months later, we declared a partnershipwith AstraZeneca to clinically evaluate bavituximab in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736) in multiple solid tumors. These collaborations with world leaders in immuno-oncology speak to the promise of bavituximab and validate our ever-growing enthusiasm for the investigational product. We look forward to advancing both of these programs and concluding enrollment of our SUNRISE trial in the next few months.”
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment and diagnosis of cancer in the United States and internationally. The company’s lead immunotherapy candidate, bavituximab, which is in Phase III development stage for the treatment of formerly-treated non-small cell lung cancer together with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
